Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45,736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
Wu P, Zhang Z, Yuan Y, Zhang C, Zhang G, Xue L, Yang H, Wang L, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Xue Q, Sun N, He J. Wu P, et al. Among authors: yang h, yang z. Int J Surg. 2022 Nov;107:106960. doi: 10.1016/j.ijsu.2022.106960. Epub 2022 Oct 17. Int J Surg. 2022. PMID: 36257585
An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma.
Zhang C, Zhang G, Sun N, Zhang Z, Xue L, Zhang Z, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Wang L, Che Y, Wang F, Wang S, Gao S, Xue Q, Zhang Y, He J. Zhang C, et al. Among authors: yang h, yang z. Signal Transduct Target Ther. 2020 Sep 4;5(1):182. doi: 10.1038/s41392-020-00221-8. Signal Transduct Target Ther. 2020. PMID: 32883946 Free PMC article.
A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy.
Zhang C, Zhang Z, Zhang G, Xue L, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Zhang Z, Wang L, Che Y, Wang S, Wang F, Fang L, Zeng Q, Li J, Gao S, Xue Q, Sun N, He J. Zhang C, et al. Among authors: yang h, yang z. Clin Transl Med. 2020 Aug;10(4):e156. doi: 10.1002/ctm2.156. Clin Transl Med. 2020. PMID: 32898328 Free PMC article.
[Quality assessment of global breast cancer screening guidelines].
Li J, Yang KL, Cai YT, Tian JH, Zheng YD, Wen Y, Yang ZY, Li N, Chen WQ, He J. Li J, et al. Among authors: yang kl, yang zy. Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Feb 10;42(2):219-226. doi: 10.3760/cma.j.cn112338-20200806-01032. Zhonghua Liu Xing Bing Xue Za Zhi. 2021. PMID: 33626607 Review. Chinese.
Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study.
Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang Z, Yang Z, Zhou A. Zhang W, et al. Among authors: yang z. Cancer Manag Res. 2021 Mar 2;13:2163-2170. doi: 10.2147/CMAR.S298360. eCollection 2021. Cancer Manag Res. 2021. PMID: 33688259 Free PMC article.
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G, Zhang C, Sun N, Xue L, Yang Z, Fang L, Zhang Z, Luo Y, Gao S, Xue Q, Mu J, Gao Y, Tan F, He J. Zhang G, et al. Among authors: yang z. J Cancer Res Clin Oncol. 2022 Apr;148(4):943-954. doi: 10.1007/s00432-021-03659-7. Epub 2021 May 19. J Cancer Res Clin Oncol. 2022. PMID: 34013382
45,736 results
You have reached the last available page of results. Please see the User Guide for more information.